In order to eradicate and predict HIV, investigators of both companies decided to develop methods to characterize potential latency candidates and discover and validate targets and pathways to eliminate infected cells and to identify biomarkers.
VGTI-FL co-director and CSO and researcher Rafick-Pierre Sekaly said the collaboration with Merck will not only allow them to enhance their discovery efforts but also to enhance their efforts to develop drugs that may help the global effort to eradicate HIV.